Margiotta V, Pizzo I, Pizzo G, Barbaro A
Department of Oral Pathology, University of Palermo, Italy.
J Oral Pathol Med. 1996 Mar;25(3):128-34. doi: 10.1111/j.1600-0714.1996.tb00207.x.
The factors associated with cyclosporin A (CsA)- and nifedipine (Nif)-induced gingival overgrowth were investigated in 113 renal transplant recipients receiving CsA alone (Group 1) [n = 61], CsA and Nif (Group 2) [n = 28], or azathioprine (Aza) (Control Group) [n = 24]. Periodontal and pharmacological parameters were assessed for each patient. The patients with a gingival overgrowth index (GOI) score >1 were considered responders (R); those with a score </= 1 were non-responders (NR). Gingival overgrowth occurred in 33.7% of the patients in Groups 1 and 2; 60% of the responders were receiving CsA+Nif. In R, no relationship was found between the GOI and the periodontal and pharmacological parameters, and although there was a trend towards an increased presence of HLA-A19 antigen (chi-square=4.40; P=0.04; RR=2.86), no significant difference was found between R and NR (Pc>0.05). It is concluded that the prevalence and severity of gingival overgrowth are greater in patients receiving CsA+Nif. As overgrowth appeared to be unrelated to local irritants, gingival inflammation or pharmacological parameters, it may be related to individual susceptibility.
在113例肾移植受者中，研究了与环孢素A（CsA）和硝苯地平（Nif）诱导的牙龈增生相关的因素。这些受者分别单独接受CsA（第1组）[n = 61]、CsA和Nif（第2组）[n = 28]或硫唑嘌呤（Aza）（对照组）[n = 24]。对每位患者的牙周和药理学参数进行了评估。牙龈增生指数（GOI）评分>1的患者被视为反应者（R）；评分≤1的患者为无反应者（NR）。第1组和第2组中33.7%的患者出现牙龈增生；60%的反应者接受CsA + Nif治疗。在反应者中，未发现GOI与牙周和药理学参数之间存在关联，尽管HLA - A19抗原的存在有增加的趋势（卡方=4.40；P = 0.04；相对危险度=2.86），但反应者与无反应者之间未发现显著差异（Pc>0.05）。得出的结论是，接受CsA + Nif治疗的患者牙龈增生的发生率和严重程度更高。由于增生似乎与局部刺激物、牙龈炎症或药理学参数无关，可能与个体易感性有关。
